{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:34:14Z","timestamp":1763480054839,"version":"3.41.0"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004382","name":"Polska Akademia Nauk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA024675"],"award-info":[{"award-number":["R01DA024675"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neurosci Ther"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7\u2010<jats:styled-content style=\"fixed-case\">OH<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DPAT<\/jats:styled-content>on the harmaline\u2010induced tremor in rats (a model of essential tremor,<jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>). To study receptor mechanisms of these drugs, rats were pretreated with dopamine D3 receptor antagonists\u2014<jats:styled-content style=\"fixed-case\">SB<\/jats:styled-content>\u2010277011\u2010A and<jats:styled-content style=\"fixed-case\">SR<\/jats:styled-content>\u201021502, an antagonist of presynaptic D2\/D3 receptors\u2014amisulpride, or a nonselective antagonist of D2\u2010like receptors, haloperidol, at a postsynaptic dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For tremor measurement, fully automated force plate actimeters were used and data were analyzed using fast Fourier transform.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Harmaline (15 mg\/kg<jats:italic>ip<\/jats:italic>)\u2010triggered tremor was manifested by an increase in the power within 9\u201315 Hz band (<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>2). Pramipexole administered at a low (0.1 mg\/kg<jats:italic>sc<\/jats:italic>), but not higher doses (0.3 and 1 mg\/kg<jats:italic>sc<\/jats:italic>), and 7\u2010<jats:styled-content style=\"fixed-case\">OH<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DPAT<\/jats:styled-content>(0.1, 0.3, and 1 mg\/kg<jats:italic>sc<\/jats:italic>) reversed the harmaline\u2010increased<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>2. None of the examined dopamine antagonists:<jats:styled-content style=\"fixed-case\">SB<\/jats:styled-content>\u2010277011\u2010A (10 mg\/kg<jats:italic>ip<\/jats:italic>),<jats:styled-content style=\"fixed-case\">SR<\/jats:styled-content>\u201021502 (15 mg\/kg<jats:italic>ip<\/jats:italic>), haloperidol (0.5 mg\/kg<jats:italic>ip<\/jats:italic>), or amisulpride (1 mg\/kg<jats:italic>ip<\/jats:italic>) influenced the above effect of dopamine agonists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study indicates that pramipexole reduces the harmaline\u2010induced tremor, which may suggest its beneficial effects in<jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>patients. However, mechanisms underlying its action are still unclear and need further examination.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cns.12467","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T17:41:38Z","timestamp":1444758098000},"page":"53-62","source":"Crossref","is-referenced-by-count":16,"title":["Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline\u2010induced Model of Essential Tremor in Rats"],"prefix":"10.1111","volume":"22","author":[{"given":"Barbara","family":"Kosmowska","sequence":"first","affiliation":[{"name":"Department of Neuro\u2010Psychopharmacology Institute of Pharmacology Polish Academy of Sciences Krak\u00f3w Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Wardas","sequence":"additional","affiliation":[{"name":"Department of Neuro\u2010Psychopharmacology Institute of Pharmacology Polish Academy of Sciences Krak\u00f3w Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"G\u0142owacka","sequence":"additional","affiliation":[{"name":"Department of Neuro\u2010Psychopharmacology Institute of Pharmacology Polish Academy of Sciences Krak\u00f3w Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Ananthan","sequence":"additional","affiliation":[{"name":"Department of Chemistry Southern Research Institute Birmingham AL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-6632","authenticated-orcid":false,"given":"Krystyna","family":"Ossowska","sequence":"additional","affiliation":[{"name":"Department of Neuro\u2010Psychopharmacology Institute of Pharmacology Polish Academy of Sciences Krak\u00f3w Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538180-000000000-00000"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14734220601016080"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2013.08.059"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(71)90174-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(92)90310-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-23-08677.2000"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(93)90108-W"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0468-09.2009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.89.309"},{"key":"e_1_2_7_11_1","first-page":"89","article-title":"Nigral degeneration correlates with persistent activation of cerebellar Purkinje cells in MPTP\u2010treated monkeys","volume":"27","author":"Heman P","year":"2012","journal-title":"Histol Histopathol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2012.08.015"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000496107"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1996.9771"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2014.11.008"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508189103"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(95)90013-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00454-2"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(96)90002-6"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039867"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31824687bf"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.17.8155"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00160-M"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.64020700.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-3565(24)36532-2","article-title":"Interactions of (+)\u2010 and (\u2010)\u20108\u2010 and 7\u2010hydroxy\u20102\u2010(di\u2010n\u2010propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotonergic and dopaminergic neurones in rats","volume":"280","author":"LeJeune F","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20759"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11653-E"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.09.026"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-78-1-7"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","article-title":"Pharmacological actions of a novel, high\u2010affinity, and selective human dopamine D3 receptor antagonist, SB\u2010277011\u2010A","volume":"294","author":"Reavill C","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.198895"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3254-y"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2014.03.055"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500801r"},{"key":"e_1_2_7_35_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker H","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","article-title":"Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity","volume":"280","author":"Perrault GH","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.04.046"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0270(01)00359-4"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.03.018"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.6.713"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.01.012"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21653"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)00066-6"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00213-5"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300018"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90335-2"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(19990301)31:3<210::AID-SYN6>3.0.CO;2-0"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.085472"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90024-X"},{"key":"e_1_2_7_50_1","first-page":"60","article-title":"In vivo occupancy of D2 dopamine receptors by 7\u2010OH\u2010DPAT","volume":"24","author":"Levant B","year":"1996","journal-title":"Synapse"},{"key":"e_1_2_7_51_1","first-page":"524","article-title":"Development and validation of GC\/MS method for determination of pramipexole in rat plasma","volume":"25","author":"Panchal JG","year":"2011","journal-title":"Chromatography"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04330.x"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2009.10.001"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-10-2"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.095661"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcns.12467","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cns.12467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:49:22Z","timestamp":1748652562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cns.12467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/cns.12467"],"URL":"https:\/\/doi.org\/10.1111\/cns.12467","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"type":"print","value":"1755-5930"},{"type":"electronic","value":"1755-5949"}],"subject":[],"published":{"date-parts":[[2015,10,13]]}}}